Orange Biomed to present microfluidic HbA1c technology at ADCES 2026

Orange Biomed will show its reagent-free HbA1c testing platform and patient education initiative at the ADCES 2026 Annual Meeting in Columbus, Ohio, Aug. 7-10. The company also plans an industry poster presentation as it works toward FDA submissions for its investigational OBM rapid A1c device.

Why it matters: - Orange Biomed is targeting diabetes care professionals with a testing platform designed to measure HbA1c without protein reagents, calibration or cold-chain storage. - The company is pairing the technology pitch with patient education efforts, signaling a push to show how diagnostics and behavior change can work together in diabetes management.

What happened: - Orange Biomed said it will participate in the Association of Diabetes Care & Education Specialists 2026 Annual Meeting in Columbus, Ohio, from Aug. 7-10. - The company will exhibit at Booth #1230 in the Greater Columbus Convention Center. - Orange Biomed will also present an Emerging Science Industry Poster titled "A novel microfluidic-based HbA1c testing method by analyzing the stiffness of red blood cells" on Saturday, Aug. 8, from 11:45 a.m. to 12:45 p.m. EDT. - The company invited conference attendees, partners and media to visit the booth and poster session.

The details: - Orange Biomed describes itself as a medical technology innovator focused on the world’s first protein-free HbA1c measurement through single-cell analysis powered by microfluidic Bio-MEMS technology. - The booth demonstration will use red blood cell models to show how the platform analyzes individual red blood cells at the single-cell level. - Orange Biomed says the platform does not require protein reagents, calibration or cold-chain storage. - ADCES brings together more than 14,000 certified diabetes care and education specialists, nurses, pharmacists, primary care providers and other healthcare professionals. - Orange Biomed’s broader education effort is called "M.A.P. Your Health," short for Monitor, Adapt, Prevent. - The initiative promotes proactive chronic disease management, daily habit building and continuous monitoring to help prevent long-term complications. - The company’s flagship product is OBM rapid A1c, a microfluidic-based A1C testing platform. - Orange Biomed is recognized in Fortune Korea’s "Top 40 Emerging South Korean Healthcare Innovations." - Orange Biomed is preparing a 510(k) submission to the FDA for potential over-the-counter clearance, followed by a point-of-care application submission. - OBM rapid A1c is an investigational device, has not been cleared by the U.S. FDA and is not available for commercial sale in the United States. - Orange Biomed provides social media channels at LinkedIn, Instagram, Facebook and YouTube.

Between the lines: - Orange Biomed is trying to position itself as more than a device maker by tying its technology to educator engagement and patient adherence. - The ADCES audience gives the company direct access to people who influence diabetes care decisions and patient education. - The FDA pathway suggests Orange Biomed is still in the pre-commercial stage in the U.S., even as it builds market awareness.

What's next: - Orange Biomed will showcase the platform and poster during the Aug. 7-10 meeting in Columbus. - The company’s next regulatory milestones are the planned FDA 510(k) submission and a later point-of-care application submission. - Orange Biomed is also likely to use the ADCES appearance to build visibility with potential partners and healthcare professionals.

The bottom line: - Orange Biomed is using ADCES 2026 to pair a new microfluidic HbA1c testing story with a broader diabetes education message as it moves toward U.S. regulatory review.